ICH E6(R3) Principles

1.1 What is Good Clinical Practice?

Understand GCP as the international ethical, scientific, and quality standard that protects research participants while ensuring reliable clinical trial data.

1.2 Historical and Ethical Foundations of GCP

Trace the evolution of research ethics from the Nuremberg Code through the Declaration of Helsinki and Belmont Report to understand why GCP protections exist.

1.3 The Global Regulatory Landscape

Navigate the international framework of clinical trial regulation, from ICH harmonization to regional requirements across FDA, EMA, PMDA, and NMPA jurisdictions.

1.4 Structure and Scope of ICH E6(R3)

Master the organization of ICH E6(R3) to locate guidance efficiently: the Principles section, Annex 1 operational requirements, Appendices, and Glossary.

2.1 Principle 1: Ethical Conduct and Participant Protection

Understand ICH E6(R3) Principle 1 and its six sub-principles that establish participant rights, safety, and well-being as the foundation of all clinical trial conduct.

2.2 Principle 2: Informed Consent Fundamentals

Understand informed consent as an ethical cornerstone requiring voluntary, informed decision-making, including requirements for legally acceptable representatives and assent.

2.3 Diversity, Inclusion, and Vulnerable Populations

Apply ICH E6(R3) Principle 1.4 to design enrollment strategies that ensure diverse participation while implementing appropriate safeguards for vulnerable populations.

2.4 Decentralized and Technology-Enabled Consent

Implement electronic and remote consent processes that maintain ethical rigor while leveraging technology to enhance participant understanding and accessibility.

3.1 Principle 3: Independent IRB/IEC review

Understand the requirement for independent ethical review by an IRB/IEC, including prior approval, continuing review, composition requirements, and procedural safeguards.

3.2 Principle 4: Scientific soundness

Understand the requirement that clinical trials be based on adequate nonclinical and clinical information, reflect current scientific knowledge, and undergo periodic review as new information emerges.

3.3 Principle 5: Qualified individuals

Understand the requirement that all individuals involved in clinical trials be qualified by education, training, and experience, including the expanded emphasis on technology and biostatistics expertise in ICH E6(R3).

3.4 IRB/IEC operations in practice

Master the practical procedures for IRB/IEC submissions, amendments, continuing review, and safety communication that ensure uninterrupted ethical oversight.

4.1 Principle 6: Quality by design

Learn how ICH E6(R3) redefines trial quality as fitness for purpose, requiring sponsors to prospectively identify critical to quality factors and build quality into trial design from the outset.

4.2 Principle 7: Proportionate approach

Learn how ICH E6(R3) requires proportionate approaches that scale trial oversight and activities to the actual risks and importance of the data collected, focusing resources where they matter most.

4.3 Principle 8: Protocol requirements

Learn how the protocol serves as the scientific and operational blueprint for clinical trials, requiring clarity, scientific soundness, and feasibility, supported by essential documents including the statistical analysis plan, data management plan, and monitoring plan.

4.4 Implementing RBQM: A practical framework

Learn how to translate quality by design and proportionality principles into actionable risk-based quality management, with practical guidance on risk identification, assessment, control, and ongoing review.

5.1 Principle 9: Reliable results

Learn how ICH E6(R3) establishes the systems, processes, and documentation requirements that ensure trial results are reliable enough to support regulatory decisions and clinical practice.

5.2 Principle 10: Roles and responsibilities

Learn how ICH E6(R3) requires clear documentation of roles and responsibilities, establishing accountability frameworks that prevent gaps and overlaps while enabling appropriate delegation with maintained oversight.

5.3 Principle 11: Investigational products

Learn how ICH E6(R3) establishes comprehensive requirements for investigational product manufacturing, handling, storage, and documentation to ensure participant safety and trial integrity.

5.4 Fit-for-purpose systems and computerized systems validation

Learn how ICH E6(R3) replaces one-size-fits-all validation with a fit-for-purpose approach, where system requirements and validation effort scale with data criticality and risk.

6.1 Qualifications, training, and resources

Learn the specific regulatory requirements for investigator qualifications, product familiarity, and resource documentation that must be established before a clinical trial begins at any site.

6.2 Responsibilities and delegation

Learn how investigators can delegate trial activities to qualified staff while retaining responsibility, implementing proportionate oversight, and maintaining documentation that enables monitoring, audit, and inspection.

6.3 Communication with IRB/IEC

Learn the specific regulatory requirements governing investigator communications with the IRB/IEC, including initial submissions, ongoing updates, and prompt reporting of changes that affect trial conduct or participant risk.

6.4 Protocol compliance and premature termination

Learn the investigator's obligations to comply with the approved protocol, properly document and report deviations, apply the immediate hazard exception correctly, and execute premature termination or suspension procedures when trials end unexpectedly.

7.1 Medical care and safety reporting

Master the investigator's dual obligation to provide qualified medical care during trial participation and to report adverse events accurately according to protocol-specified timelines.

7.2 Informed consent of trial participants

Master the comprehensive requirements for obtaining, documenting, and maintaining informed consent, including required document elements, re-consent procedures, and consent for participants who cannot consent themselves.

7.3 End of participation and IP management

Master end-of-participation procedures including withdrawal versus discontinuation distinctions, follow-up requirements, and comprehensive investigational product accountability from receipt through final disposition.

7.4 Randomization and unblinding

Master the investigator's responsibilities for maintaining randomization integrity, protecting blinding throughout trial conduct, and executing emergency unblinding procedures when participant safety requires it.

8.1 Records and source documentation

Master the fundamental requirements for maintaining accurate, complete, and legible trial records, distinguishing source documents from derived data, and applying ALCOA+ principles to all documentation.

8.2 Reports to IRB/IEC and sponsor

Master the investigator's reporting obligations throughout the trial lifecycle, including progress reports, safety reports, and final reports to both the IRB/IEC and sponsor.

8.3 Data governance fundamentals

Master the new Section 4 data governance requirements of ICH E6(R3), including safeguarding blinding, managing the data lifecycle, and executing proper data corrections, transfers, and finalization.

8.4 Computerized systems requirements

Master the specific requirements of ICH E6(R3) Section 4.3 for computerized systems, including procedures, training, security, validation, release, failure management, support, and user access controls.